Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Lymphoma 3Ovarian Neoplasms 2Melanoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Microsatellite Instability 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 4Paclitaxel 2vocimagene amiretrorepvec 1stenoparib 1olaparib 1mirabegron 1epacadostat 1durvalumab 1ciforadenant 1cemiplimab 1atezolizumab 1advexin 1Temozolomide 1Rituximab 1Pharmacogenomic Variants 1Nivolumab 1LTX-315 1Ipilimumab 1IACS-010759 1HMPL-013 1Gemcitabine 1Fluorodeoxyglucose F18 1Flucytosine 1Carboplatin 1Capecitabine 1CPI-006 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1Antibodies 1AZD5153 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × epacadostat × Lymphoid × Clear all
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡